{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:33:39Z","timestamp":1776756819401,"version":"3.51.2"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1990,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1093\/annonc\/mdu134","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T01:09:32Z","timestamp":1396400972000},"page":"1152-1158","source":"Crossref","is-referenced-by-count":40,"title":["Activity of trabectedin in germline BRCA1\/2-mutated metastatic breast cancer: results of an international first-in-class phase II study"],"prefix":"10.1016","volume":"25","author":[{"given":"S.","family":"Delaloge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Wolp-Diniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Byrski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Campone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cullell-Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lubinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu134_bb0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdu134_bb0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu134_bb0020","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdu134_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-009-0566-z","article-title":"Prognosis of BRCA-associated breast cancer: a summary of evidence","volume":"119","author":"Bordeleau","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu134_bb0030","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","article-title":"Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Graeser","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu134_bb0035","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","article-title":"Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer","volume":"24","author":"Pierce","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu134_bb0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","article-title":"The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers","volume":"96","author":"Metcalfe","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdu134_bb0045","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdu134_bb0050","doi-asserted-by":"crossref","first-page":"13062","DOI":"10.1073\/pnas.0609877104","article-title":"Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743","volume":"104","author":"Soares","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdu134_bb0055","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1158\/1535-7163.MCT-07-2432","article-title":"Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin","volume":"7","author":"Casado","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdu134_bb0060","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): a unique mechanism of action","volume":"9","author":"D'Incalci","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdu134_bb0065","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ejca.2011.01.016","article-title":"Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study","volume":"47","author":"Schoffski","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu134_bb0070","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ejca.2008.11.019","article-title":"Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer","volume":"45","author":"Sessa","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu134_bb0075","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.bjc.6603142","article-title":"A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer","volume":"94","author":"Zelek","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdu134_bb0080","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/jco.2005.23.16_suppl.625","article-title":"Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens","volume":"23","author":"Gurtler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu134_bb0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdu134_bb0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu134_bb0095","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O'Brien","year":"1979","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdu134_bb0100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"10.1093\/annonc\/mdu134_bb0105","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","article-title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdu134_bb0110","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/1535-7163.MCT-12-0768","article-title":"Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response","volume":"12","author":"Garcia","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdu134_bb0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdu134_bb0120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/cbt.8.7.7968","article-title":"Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo","volume":"8","author":"Tassone","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdu134_bb0125","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/jco.2009.27.15_suppl.502","article-title":"Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients","volume":"27","author":"Gronwald","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu134_bb0130","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1158\/1535-7163.MCT-11-0252","article-title":"Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells","volume":"10","author":"Soares","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdu134_bb0135","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu134_bb0140","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/14656566.9.9.1609","article-title":"Clinical impact of trabectedin (ecteinascidin-743) in advanced\/metastatic soft tissue sarcoma","volume":"9","author":"Schoffski","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1093\/annonc\/mdu134_bb0145","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/annonc\/mdr399","article-title":"Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer","volume":"23","author":"Michaelson","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu134_bb0150","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12032-012-0435-1","article-title":"Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials","volume":"30","author":"Del Campo","year":"2013","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdu134_bb0155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.lungcan.2011.12.002","article-title":"Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and\/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum","volume":"76","author":"Massuti","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdu134_bb0160","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/annonc\/mdr265","article-title":"Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma","volume":"23","author":"Gronchi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu134_bb0165","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","article-title":"Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study","volume":"23","author":"Garcia-Carbonero","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:44:29Z","timestamp":1624520669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419365871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0923753419365871"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu134","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}